Malme-3MHomo sapiens (Human)Cancer cell line
Also known as: MALME-3M, MALME 3M, Malme-3 M, MALME.3M, Malme3M, MALME3M, Malme-3 Monolayer, MALME 37, MELM-3M
Quick Overview
Human melanoma cell line with known BRAF mutations and genetic diversity.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
Database ID | CVCL_1438 |
---|---|
Species | Homo sapiens (Human) |
Tissue Source | Lung[UBERON:UBERON_0002048] |
Donor Information
Age | 43 |
---|---|
Age Category | Adult |
Sex | Male |
Race | caucasian |
Disease Information
Disease | Melanoma |
---|---|
Lineage | Skin |
Subtype | Melanoma |
OncoTree Code | MEL |
DepMap Information
Source Type | ATCC |
---|---|
Source ID | ACH-000477_source |
Known Sequence Variations
Type | Gene/Protein | Description | Zygosity | Note | Source |
---|---|---|---|---|---|
Gene deletion | CDKN2A | - | Homozygous | Possible | PubMed=26870271 |
MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
MutationSimple | TERT | c.1-124C>T (c.228C>T) (C228T) | Unspecified | In promoter | from parent cell line Hep-G2 |
MutationNone reported | TP53 | - | - | - | PubMed=19787792 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Genetic alterations in main candidate genes during melanoma progression.
Manca A., Botti G., Ascierto P.A., Lissia A., Cossu A., Palmieri G.
Oncotarget 9:8531-8541(2018).
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Nat. Commun. 10:3574.1-3574.11(2019).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
New human tumor cell lines.";
Fogh J., Trempe G.L.
(In book chapter) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York; USA (1975).
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
Fogh J., Fogh J.M., Orfeo T.
J. Natl. Cancer Inst. 59:221-226(1977).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines.
Gray-Goodrich M., Campbell H., Mayo J.G., Boyd M.R.
J. Natl. Cancer Inst. 83:757-766(1991).
Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay.
Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R.
Cancer Res. 48:589-601(1988).
Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis.
Wright W.C., Daniels W.P., Fogh J.
J. Natl. Cancer Inst. 66:239-247(1981).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Rousset M., Zweibaum A., Fogh J.
Cancer Res. 41:1165-1170(1981).
Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer.
van Zijl P.L.
Eur. J. Cancer 31A:230-237(1995).
Radiosensitivity of new and established human melanoma cell lines: comparison of [3H]thymidine incorporation and soft agar clonogenic assays.
Finlay G.J., Holdaway K.M., Baguley B.C.
Eur. J. Cancer 30A:1370-1376(1994).
Systematic variation in gene expression patterns in human cancer cell lines.
Botstein D., Brown P.O.
Nat. Genet. 24:227-235(2000).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
J. Invest. Dermatol. 122:337-341(2004).
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.
Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.
Mol. Cancer Ther. 5:2606-2612(2006).
DNA fingerprinting of the NCI-60 cell line panel.";
Chanock S.J., Weinstein J.N.
Mol. Cancer Ther. 8:713-724(2009).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Haber D.A.
Cancer Res. 70:2158-2164(2010).
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
Ambudkar S.V., Gottesman M.M.
Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011).
Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location.
Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C.
PLoS ONE 7:E31628-E31628(2012).
Identification of cancer cell-line origins using fluorescence image-based phenomic screening.
Yoon C.N., Chang Y.-T.
PLoS ONE 7:E32096-E32096(2012).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.
Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.
Science 336:1040-1044(2012).
Functional profiling of live melanoma samples using a novel automated platform.
Schuchter L.M., Clark D.P.
PLoS ONE 7:E52760-E52760(2012).
The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology.
Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.
Cancer Res. 73:4372-4382(2013).
Global proteome analysis of the NCI-60 cell line panel.";
Wilhelm M., Kuster B.
Cell Rep. 4:609-620(2013).
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates.
Hirshfield K.M., Oltvai Z.N., Vazquez A.
Cancer Metab. 1:20.1-20.13(2013).
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Rosen N., Solit D.B.
Cancer Res. 74:2340-2350(2014).
High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner.
Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.
PLoS ONE 9:E92047-E92047(2014).
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Davies M.A., Mills G.B., Chin L.
Cancer Res. 74:4845-4852(2014).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR.
Vandesompele J.
Sci. Data 3:160052-160052(2016).
A map of mobile DNA insertions in the NCI-60 human cancer cell panel.
Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.
Mob. DNA 7:20.1-20.11(2016).